Pieris Pharmaceuticals, Inc.(PIRS)

Description: Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

---

Keywords: Medicine Cancer Asthma Dialysis Inflammatory Diseases Kidney Disease Membrane Technology Chronic Kidney Disease Kidney Carcinoma Sarcoma Renal Disease Hepatology Blood Plasma End Stage Renal Disease Iron Deficiency Stage Renal Disease Treatment Of Various Types Of Cancers Central Nervous System Tumors Hepcidin

---

Home Page: www.pieris.com

PIRS Technical Analysis

255 State Street
Boston, MA 02109
United States
Phone: 857 246 8998

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)